Park Seon-Young, Seo Geom Seog
Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.
Department of Internal Medicine, Digestive Disease Research Institute, Wonkwang University College of Medicine, Iksan, Korea.
Clin Endosc. 2021 Mar;54(2):157-160. doi: 10.5946/ce.2021.072. Epub 2021 Mar 30.
Fecal microbiota transplantation (FMT) is an accepted procedure for the management of recurrent Clostridioides difficile infections. FMT is generally considered safe and well-tolerated - even in high-risk patients. Most short-term risks are mild and known to be associated with delivery methods. Long-term side effects have not been established, and no signs of harm have been found to date. However, causality for several microbiome-associated diseases has to be established. Even though FMT is generally considered safe with strict donor screening, serious adverse events have been recently associated with the FMT product from the stool bank, where screening for multi-drug resistant organisms is not included in protocols. Here, we discuss the adverse events associated with FMT and safety issues.
粪便微生物群移植（FMT）是治疗复发性艰难梭菌感染的一种公认方法。FMT通常被认为是安全且耐受性良好的——即使在高危患者中也是如此。大多数短期风险较为轻微，且已知与给药方式有关。长期副作用尚未明确，迄今为止也未发现有害迹象。然而，必须确定几种与微生物群相关疾病的因果关系。尽管通过严格的供体筛查，FMT通常被认为是安全的，但最近严重不良事件与粪便库的FMT产品有关，而粪便库的方案中未包括对多重耐药菌的筛查。在此，我们讨论与FMT相关的不良事件和安全问题。
